Request Trial
lightspring-money-competition
Lightspring / Shutterstock.com
29 August 2023FeaturesPharmaAndrei Iancu and David Kappos

Everybody loses in the end: Billion-dollar government prizes won't improve on market incentives

In his latest attempt to replace America's free market with government regulators to set prices for medicines, Senator Bernie Sanders wants to reward drug developers with cash prizes determined in Washington. In his vision, these would replace the current US patent system.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Pharma
GSK lands 36-country injunction in Pfizer-BioNTech vaccine litigation
12 November 2026   Handing the pharma giant a major win in its feud with Pfizer and BioNTech, the UPC’s injunction reaches well beyond the court’s member states. But with an appeal still possible and parallel disputes playing out across the US and Europe, the fight is far from over.
Pharma
‘No medicine is off limits’: US Chamber of Commerce says stricter import rules may deter fakes
12 November 2026   From GLP-1 drugs to cancer treatments, counterfeiters are exploiting supply chain weaknesses and AI to evade detection. The US chamber’s director of IP tells LSIPR why the fight against fakes is becoming more complex and what lies ahead.
Pharma
Eli Lilly follows Novo in UK High Court bid to block ‘black-market websites’
10 November 2026   The pharma giant has filed a trademark and passing off claim in London to try and prevent UK consumers from accessing fake weight-loss drugs and other prescription medicines, after its rival’s success in a similar claim earlier in 2026.


Editor's picks

In-house counsel rethink patent filing strategies as costs mount
In-house counsel
In-house counsel rethink patent filing strategies as costs mount
3 November 2026

Editor's picks

In-house counsel
In-house counsel rethink patent filing strategies as costs mount
3 November 2026
Pharma
Boehringer accuses Dr Reddy’s of ‘weaponising’ plausibility
20 October 2026
MedTech
Boston Scientific expands dispute with J&J unit over cardiac-access technology
12 October 2026
Pharma
Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
6 October 2026
In-house counsel
WATCH: Genevant IP director on tackling UPC-EPO opposition divide
1 October 2026
Pharma
Lilly loses Fed Circ rehearing bid, sparking enablement questions
1 October 2026

More features

South Korean biotech takes aim at US medtech leader over alleged cell-washing tech theft
GSK lands 36-country injunction in Pfizer-BioNTech vaccine litigation
‘No medicine is off limits’: US Chamber of Commerce says stricter import rules may deter fakes
GSK and Moderna settle cross-border patent dispute over vaccine tech
Eli Lilly follows Novo in UK High Court bid to block ‘black-market websites’
How in-house teams can get more value from external counsel
Settled expectations, the six-year rule, and developments in USPTO policy
Regulatory and patent teams must align, say Amgen, Genentech, ORIC